A Phase II Open-Label Exploratory Study of Saquinavir + Zidovudine + Lamivudine in HIV Infected Patients

A Phase II Open-Label Exploratory Study of Saquinavir + Zidovudine + Lamivudine in HIV Infected Patients

To explore the antiviral efficacy, tolerability and safety of saquinavir plus zidovudine plus lamivudine.

A total of 30 patients receive the triple drug regimen saquinavir plus zidovudine plus lamivudine until the completion of the analysis after at least 4 weeks of therapy.

Inclusion Criteria

Patients must have:

• HIV antibody positive.
• CD4 count >= 150 and <= 500 cells/mm3.

Exclusion Criteria

Prior Medication:

Excluded:

• Prior antiretroviral therapy.
• Prior protease inhibitor therapy.